Enable Biosciences Inc. Welcomes Will Robberts as New CFO

Enable Biosciences Inc., an innovative diagnostic healthcare company renowned for its early disease detection technology, is pleased to announce the appointment of Will Robberts as the Chief Financial Officer (CFO). This significant addition to the leadership team coincides with the company securing undisclosed equity financing, marking a pivotal moment in its pursuit of advancing diagnostic solutions on a global scale.

Will Robberts joins Enable Biosciences with over twenty years of distinguished experience in finance and operations across the healthcare, software, and technology sectors. His prior roles include President and CFO at LIPAC Oncology and TesoRx Pharma, where he was instrumental in driving growth through successful financings, and spearheading multinational partnering and licensing deals. Robberts’ career also boasts senior positions at Thomson Reuters, Esquire Deposition Solutions, KPMG, Softline, and LiveNote, contributing to significant organizational growth, mergers and acquisitions, and investor exits.

A University of Johannesburg alumnus, Robberts has attained Bachelor’s, Honors, and Master’s degrees in Accounting, Economics, and Financial Management. His leadership extends beyond Enable Biosciences, serving on the boards of several pharmaceutical and technology companies, demonstrating his dedication to meeting the healthcare and technology sectors’ unmet needs.

David Seftel, M.D., CEO of Enable Biosciences, expressed enthusiasm about Robberts’ appointment, emphasizing his pivotal role in acquiring the funding necessary for the company’s strategic initiatives. “Will’s exceptional track record in finance and operations makes him a valuable asset to our team. His contributions are set to accelerate our mission to revolutionize early disease detection,” said Seftel.

Robberts shared his excitement about joining Enable Biosciences, highlighting the company’s innovative DNA-barcoding antibody detection technology co-invented by Enable co-founder and 2022 Chemistry Nobel Laureate Prof. Carolyn Bertozzi. “I am thrilled to be part of Enable’s journey at such a crucial stage of its growth cycle. The potential of Enable’s technology to transform patient care is immense, and I am eager to contribute to the company’s success,” Robberts stated.

About Enable Biosciences Inc.:

Situated in South San Francisco, Enable Biosciences Inc. stands at the forefront of diagnostic healthcare innovation. The company’s commitment to enhancing patient care through early disease detection spans across four continents. Leveraging ultrasensitive and highly specific diagnostic solutions, Enable Biosciences aims to improve patient outcomes by identifying diseases at their earliest stages, embodying its mission to detect disease when it matters most.